These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 16890795

  • 1. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L, Trail PA, Taylor I, Wilhelm SM.
    Methods Enzymol; 2006 Dec 15; 407():597-612. PubMed ID: 16757355
    [Abstract] [Full Text] [Related]

  • 4. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 15; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 5. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 6. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
    Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B.
    Oncologist; 2007 Apr 01; 12(4):426-37. PubMed ID: 17470685
    [Abstract] [Full Text] [Related]

  • 7. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
    Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, Ghofrani HA, Grimminger F, Busch AE, Schäfer S.
    Circulation; 2008 Nov 11; 118(20):2081-90. PubMed ID: 18955668
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.
    Cancer Res; 2009 Aug 15; 69(16):6515-21. PubMed ID: 19638574
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I, Pollak Y, Broneshter R, Iancu TC.
    FEBS J; 2011 Sep 15; 278(18):3494-507. PubMed ID: 21790999
    [Abstract] [Full Text] [Related]

  • 10. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ, Der CJ.
    Oncogene; 2007 May 14; 26(22):3291-310. PubMed ID: 17496923
    [Abstract] [Full Text] [Related]

  • 11. Targeted agents for the treatment of advanced renal cell carcinoma.
    Stadler WM.
    Cancer; 2005 Dec 01; 104(11):2323-33. PubMed ID: 16240452
    [Abstract] [Full Text] [Related]

  • 12. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 01; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 13. Raf: a strategic target for therapeutic development against cancer.
    Beeram M, Patnaik A, Rowinsky EK.
    J Clin Oncol; 2005 Sep 20; 23(27):6771-90. PubMed ID: 16170185
    [Abstract] [Full Text] [Related]

  • 14. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Sep 20; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 15. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.
    J Hepatol; 2010 Jan 20; 52(1):79-87. PubMed ID: 19910069
    [Abstract] [Full Text] [Related]

  • 16. B-Raf kinase inhibitors for cancer treatment.
    Li N, Batt D, Warmuth M.
    Curr Opin Investig Drugs; 2007 Jun 20; 8(6):452-6. PubMed ID: 17621874
    [Abstract] [Full Text] [Related]

  • 17. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
    McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, Steelman LS.
    Curr Opin Investig Drugs; 2008 Jun 20; 9(6):614-30. PubMed ID: 18516761
    [Abstract] [Full Text] [Related]

  • 18. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S, Djelloul S, Raymond E.
    Semin Oncol; 2006 Aug 20; 33(4):407-20. PubMed ID: 16890796
    [Abstract] [Full Text] [Related]

  • 19. Raf pathway inhibitors in oncology.
    Bollag G, Freeman S, Lyons JF, Post LE.
    Curr Opin Investig Drugs; 2003 Dec 20; 4(12):1436-41. PubMed ID: 14763129
    [Abstract] [Full Text] [Related]

  • 20. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV, Robertson GP.
    Cancer Res; 2008 Jan 01; 68(1):5-8. PubMed ID: 18172288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.